Cargando…

Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL)

Recent success of novel therapies has improved treatment of chronic lymphocytic leukemia (CLL) patients, but most of them still require several treatment regimes. To improve treatment choice, prognostic markers suitable for prediction of disease outcome are required. Several molecular/genetic marker...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kaban, Kübra, Greiner, Sarah M., Holzmayer, Samuel, Tandler, Claudia, Meyer, Sophie, Hinterleitner, Clemens, Salih, Helmut R., Märklin, Melanie, Heitmann, Jonas S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8622208/ https://www.ncbi.nlm.nih.gov/pubmed/34829391 http://dx.doi.org/10.3390/diagnostics11112041

Ejemplares similares

Identification of CD105 (endoglin) as novel risk marker in CLL
por: Greiner, Sarah M., et al.
Publicado: (2022)

DNAM-1/CD226 is functionally expressed on acute myeloid leukemia (AML) cells and is associated with favorable prognosis
por: Chashchina, Anna, et al.
Publicado: (2021)

CD105 (Endoglin) as negative prognostic factor in AML
por: Kauer, Joseph, et al.
Publicado: (2019)

BCR::ABL1 tyrosine kinase inhibitors hamper the therapeutic efficacy of blinatumomab in vitro
por: Kauer, Joseph, et al.
Publicado: (2022)

Therapeutic Silencing of BCL-2 Using NK Cell-Derived Exosomes as a Novel Therapeutic Approach in Breast Cancer
por: Kaban, Kübra, et al.
Publicado: (2021)

Genetic Loss of LCK Kinase Leads to Acceleration of Chronic Lymphocytic Leukemia
por: Märklin, Melanie, et al.
Publicado: (2020)

Identification of CD318 (CDCP1) as novel prognostic marker in AML
por: Heitmann, Jonas S., et al.
Publicado: (2020)

Expression of the immune checkpoint modulator OX40 indicates poor survival in acute myeloid leukemia
por: Marconato, Maddalena, et al.
Publicado: (2022)

Platelets subvert antitumor efficacy of T cell-recruiting bispecific antibodies
por: Lutz, Martina Svenja, et al.
Publicado: (2022)

Neutralization of B-Cell Activating Factor (BAFF) by Belimumab Reinforces Small Molecule Inhibitor Treatment in Chronic Lymphocytic Leukemia
por: Tandler, Claudia, et al.
Publicado: (2020)

Platelet-Expressed TNFRSF13B (TACI) Predicts Breast Cancer Progression
por: Hinterleitner, Clemens, et al.
Publicado: (2021)

Bispecific NKG2D-CD3 and NKG2D-CD16 Fusion Proteins as Novel Treatment Option in Advanced Soft Tissue Sarcomas
por: Hagelstein, Ilona, et al.
Publicado: (2021)

B7-H3-targeting Fc-optimized antibody for induction of NK cell reactivity against sarcoma
por: Hagelstein, Ilona, et al.
Publicado: (2022)

An Fc-Optimized CD133 Antibody for Induction of NK Cell Reactivity against B Cell Acute Lymphoblastic Leukemia
por: Riegg, Fabian, et al.
Publicado: (2021)

Not all lymphoid aggregates in chronic lymphocytic leukemia (CLL) patients are due to CLL!
por: Mahapatra, Lily, et al.
Publicado: (2021)

Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
por: Odetola, Oluwatobi, et al.
Publicado: (2023)

Regulation of Platelet-Derived ADAM17: A Biomarker Approach for Breast Cancer?
por: Zhou, Yanjun, et al.
Publicado: (2021)

Immunological aspects in chronic lymphocytic leukemia (CLL) development
por: García-Muñoz, Ricardo, et al.
Publicado: (2012)

Physiological Fitness and the Pathophysiology of Chronic Lymphocytic Leukemia (CLL)
por: Sitlinger, Andrea, et al.
Publicado: (2021)

Targeting NKG2DL with Bispecific NKG2D–CD16 and NKG2D–CD3 Fusion Proteins on Triple–Negative Breast Cancer
por: Kaidun, Polina, et al.
Publicado: (2023)

Rapid transitions in the standard of care for chronic lymphocytic leukemia (CLL)
por: Seymour, Erlene K.
Publicado: (2019)

Leukemia Cutis as an Early Presentation or Relapsing Manifestation of Chronic Lymphocytic Leukemia (CLL)
por: Aldapt, Mahmood B, et al.
Publicado: (2021)

Cause of death in patients with newly diagnosed chronic lymphocytic leukemia (CLL) stratified by the CLL-International Prognostic Index
por: Wang, Yucai, et al.
Publicado: (2021)

Sequential treatment with bendamustine, obinutuzumab (GA101) and Ibrutinib in chronic lymphocytic leukemia (CLL): final results of the CLL2-BIG trial
por: von Tresckow, Julia, et al.
Publicado: (2022)

Appearance and Disappearance of Chronic Myeloid Leukemia (CML) in Patient with Chronic Lymphocytic Leukemia (CLL)
por: Payandeh, Mehrdad, et al.
Publicado: (2014)

Diagnosis and Treatment of Chronic Lymphocytic Leukemia: Recommendations of the French CLL Study Group (FILO)
por: Quinquenel, Anne, et al.
Publicado: (2020)

Population Pharmacokinetics of Obinutuzumab (GA101) in Chronic Lymphocytic Leukemia (CLL) and Non-Hodgkin's Lymphoma and Exposure–Response in CLL
por: Gibiansky, E, et al.
Publicado: (2014)

Platelet-expressed immune checkpoint regulator GITRL in breast cancer
por: Zhou, Yanjun, et al.
Publicado: (2021)

Mechanisms and consequences of the loss of PHLPP1 phosphatase in chronic lymphocytic leukemia (CLL)
por: O'Hayre, M, et al.
Publicado: (2012)

Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
por: Montillo, Marco, et al.
Publicado: (2008)

Guidelines for Diagnosis and Treatment of Chronic Lymphocytic Leukemia. Krohem B-Cll 2017
por: Jakšić, Branimir, et al.
Publicado: (2018)

Role of Chronic Lymphocytic Leukemia (CLL)-Derived Exosomes in Tumor Progression and Survival
por: Nisticò, Nancy, et al.
Publicado: (2020)

Characterization of anticoagulant heparinoids by immunoprofiling
por: Wijnhoven, Tessa J., et al.
Publicado: (2007)

Chronic lymphocytic leukemia (CLL) with Reed–Sternberg-like cells vs Classic Hodgkin lymphoma transformation of CLL: does this distinction matter?
por: King, Rebecca L., et al.
Publicado: (2022)

The spectrum of coincident entities with small lymphocytic lymphoma/chronic lymphocytic leukemia (SLL/CLL) diagnosed by cytology
por: Kastenbaum, Hannah A., et al.
Publicado: (2010)

Tocilizumab, but not dexamethasone, prevents CRS without affecting antitumor activity of bispecific antibodies
por: Kauer, Joseph, et al.
Publicado: (2020)

Immunotherapy in Chronic Lymphocytic Leukaemia (CLL)
por: Freeman, Ciara L., et al.
Publicado: (2016)

PI3K Signaling in Normal B Cells and Chronic Lymphocytic Leukemia (CLL)
por: Okkenhaug, Klaus, et al.
Publicado: (2015)

Genomic characterization of chronic lymphocytic leukemia (CLL) in radiation-exposed Chornobyl cleanup workers
por: Ojha, Juhi, et al.
Publicado: (2018)

Disseminated cryptococcal infection in a patient with treatment-naïve chronic lymphocytic leukemia (CLL)
por: Suleman, Adam, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_n5al1qhkq2esie0n0fd7imdefu